論文

査読有り
2020年5月23日

Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.

Breast cancer (Tokyo, Japan)
  • Tomoharu Sugie
  • Eiichi Sato
  • Minoru Miyashita
  • Rin Yamaguchi
  • Takashi Sakatani
  • Yuji Kozuka
  • Suzuko Moritani
  • Eiji Suzuki
  • Kazuhiro Kakimi
  • Yoshiki Mikami
  • Takuya Moriya
  • 全て表示

27
4
開始ページ
519
終了ページ
526
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s12282-020-01110-2

BACKGROUND: Programmed death-ligand 1 (PD-L1) expression on immune cells (ICs) is a predictive marker for PD-L1 checkpoint blockade in patients with triple-negative breast cancer (TNBC). However, the level of PD-L1 expression and the percentage of cells that are PD-L1+ are continuous variables not dichotomous variables for tumor-infiltrating lymphocytes (TILs) and other cells. METHODS: Multiplexed immunohistochemistry was applied to 31 archived surgical specimens from untreated TNBC patients. TIL levels were visually scored, and CD8+ T cells and PD-L1+ ICs were quantified using an automated multispectral imaging system. PD-L1 expression was assessed within a multiplexed context (CD8 combined spectral composite). RESULTS: The mean value of stromal TILs (i.e., the percentage of the stromal area with a dese mononuclear infiltrate) was 20%. The frequency of patients with PD-L1-positive tumor cells (TC) and ICs was 38.7% and 32.2%, respectively, with a significant association between them. TIL levels were correlated with CD8+ T cell infiltration in the stroma (Spearman r = 0.795, p < 0.0001). PD-L1 expression on IC was significantly associated with TIL levels (Spearman r = 0.790, p < 0.001) and infiltration of CD8+ T cells (Spearman r = 0.683, p < 0.0001). CONCLUSIONS: The level of PD-L1 on IC was correlated with the level of PD-L1 on TC as well as TIL levels and infiltration of CD8+ T cells. These results suggest that high PD-L1 on IC may reflect T cell-inflamed tumors with the amount of TILs present, including the CD8+ T cells required for anti-tumor responses.

リンク情報
DOI
https://doi.org/10.1007/s12282-020-01110-2
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32447649
ID情報
  • DOI : 10.1007/s12282-020-01110-2
  • PubMed ID : 32447649

エクスポート
BibTeX RIS